INTRODUCTION
The a-globulins of human serum contain several protease inhibitors: al-antitrypsin (ai-AT),' ai-antichymotrypsin, inter-a trypsin inhibitor, and a2-macroglobulin. The al-AT is the major trypsin inhibitor, but can also inhibit bacterial enzymes (1) , the neutral protease and elastase (2) (3) (4) derived from lysosomal granules of neutrophilic granulocytes, skin collagenase (5), plasmin (6) , and thrombin (4) . Each of these inhibitors interacts in what appears to be a stoichiometric manner with the target enzyme binding with it and leading to its inactivation.
A second type of inhibitor has been described in the a-globulins of human serum: a carboxypeptidase B-like Received for publication 25 'Abbreviations used in this paper: a,-AT, al antitrypsin;
BSA, bovine serum albumin.
enzyme that inactivates two classes of biologically active peptides: the kinins generated by kallikrein (7) and the anaphylatoxins that emanate *as cleavage products from the third and fifth components of complement (8) .
Because of the ability of the carboxypeptidase B-like enzyme to inactivate the anaphylatoxins, it has been termed the anaphylatoxin inactivator (9) . Recently another inactivator has been isolated from the a-globulin region of human serum: the chemotactic factor inactivator (10) . This inhibitor appears to act in an enzymatic-like fashion to inactivate complement-derived and complement-independent chemotactic factors. This paper will record the observation that sera deficient in the a, antitrypsin are also deficient in the chemotactic factor inactivator. This finding may bear on the mechanisms responsible for development of pulmonary emphysema in patients who have severe a, antitrypsin deficiency. METHODS Sera. Five different human sera lacking >80% of the a,-AT as judged by measurements of trypsin inhibitory capacity and a,-AT concentration (11) were used in these studies. By convention, the genotyping of these sera is PiZZ (12) . In addition, one serum was used (An) from an individual with no detectable a,-AT. Each of these patients has severe, chronic pulmonary emphysema and is seriously ill. In order to determine whether the clinical condition of severe pulmonary emphysema is directly related to the status of the chemotactic factor inactivator in serum, sera from six different patients with chronic, progressive pulmonary emphysema were also studied. In each of these sera the level of a,-AT was at least 50% of the level in normal control serum. Sera from five normal humans, containing > 50% the normal levels of the a, antitrypsin, were also used. Some of these preparations were generously provided as fresh frozen sera by Dr. Chester Alper.
Chemotaxis. Modified Boyden chambers employing micropore filters of 650 nm pore size were used for chemotaxis assays (13 (14) . In the first part of this study culture filtrates from a 24 h growth of Escherichia coli in medium 199 were used as the source of chemotactic factor (15) In the other experiments serum (0.1 ml) was chemotactically activated with immune precipitates. 
RESULTS
Lack of chemotactic factor inactivator in sera-dficient in at antitrypsin. \Vhen the soluble ammonium sulfate fractions of four normal human sera were incubated with the bacterial chemotactic factor, 70-80% inhibition of the chemotactic activity resulted (Table I ). The loss of activity reflects the action of the chemotactic factor inactivator present in the concentrated fraction of normal serum. The serum fractions from six different patients with chronic, progressive pulmonary emphysema were each found to contain significant inhibitory activity for the chemotactic factor. It was previously determined that in each of these sera there were substantial levels of a,-AT (see above). In contrast, in spite of the fact that four different human sera, each deficient in the trypsin inhibitor, were fractionated and concentrated in the same manner, inhibitory activity for the bacterial chemotactic factor was lacking, or present in much lower quantity (Table I ). The lack of an immunological assay for the chemotactic factor inactivator has not allowed determination of precise levels of the inactivator in the individual sera. These data indicate that serum deficiencies of the chemotactic factor inactivator are associated with ai-AT deficiency, but not with the clinical condition of pulmonary emphysema per se.
In order to determine if ai-AT-deficient serum had a blocking effect on the expression of the activity of the chemotactic factor inactivator, 50 ,l of the chemotactic factor inactivator (prepared from normal serum according to the details listed above) was added to 50 Al of normal human serum and to an al-AT-deficient serum.
No loss in the ability of the inactivator to inhibit the chemotactic factor was noted in the two sera (81% inhibition vs. 85% inhibition in the normal and the ai-ATleficient serum, respectively). These results suggest that the loss of chemotactic factor inactivator in the ai-ATdeficient sera is not due to impairment of an existent inactivator in these sera.
The generation of super-normal amounts of chemotactic activity in inhibitor-deficient sera. Since it is now established that the chemotactic factor inactivator inhibits the complement-derived chemotactic factors (C3 and C5 fragments, C567) as well as the bacterial chemotactic factor (10) , it became of interest to determine the amount of chemotactic activity generated in normal sera and in those sera lacking the chemotactic factor inactivator (along with a,-AT). This experiment was done in view of the knowledge that when human serum is chemotactically activated, the resulting chemotactic activity is ascribable to C5 products (13, 14) , these factors being susceptible to the action of the chemotactic factor inactivator derived from normal human serum (10) . The data in Table II compare the amounts of chemotactic activity generated in five normal sera and five aL-AT-deficient sera after incubation with immune complexes. The amount of chemotactic activity generated in the al-AT-deficient sera is two-to threefold greater than the activity generated in normal (ai-AT-sufficient) human serum. In view of the data in Table I , these findings are not surprising. DISCUSSION It can be concluded from these experiments that those sera deficient in the a,-AT are also deficient in the chemotactic factor inactivator. The most obvious possibility to explain such an association would be identity of the two inhibitors. Evidence so far is against this likelihood. Operationally, the two inhibitors work in quite different ways. The al-AT binds to the enzyme in stoichiometric fashion to render it inactive. In studies with the chemotactic factor inactivator, all evidence of binding to the radiotagged C5 chemotactic fragment has been negative (10) . It seems probable that the inactivator of chemotactic activity destroys the chemotactic factor in an enzymatic manner, such as kininases destroy kinins (7) . A second point that tends to distinguish the two inhibitors is estimates of molecular weight. The ai-AT has a molecular weight of 45,000, while estimates of the chemotactic factor inactivator suggest the presence of two inhibitors in serum, which may have molecular weights considerably above or below the figure of 45,000 (10) . Whether the chemotactic factor inactivator is or is not identical with a,-AT or with the anaphylatoxin inactivator is a minor consideration in the context of this paper. The message of this report is the lack of the chemotactic factor inactivator in sera deficient in ai-AT.
The data also suggest that the deficiency of the chemotactic factor inactivator is not associated per se with the condition of pulmonary emphysema, since ai-AT-sufficient serum from patients with chronic progressive pulmonary emphysema have substantial levels in the serum of the chemotactic factor inactivator. Further, it appears that the lack of chemotactic factor inactivator in an-ATdeficient serum is an actual loss of the inactivator rather than its impairment.
It has been suggested that a high percentage of patients with deficiency of al-AT develop pulmonary emphysema because the trypsin-like enzymes, including elastase and the neutral proteases derived from lysosomal granules of neutrophilic granulocytes (3), react in an uncontrolled fashion. The data in this paper indicate a second possibility must also be considered: the deficiency or absence of the naturally occurring chemotactic factor inactivator in the serum of the same patients (Table I) could mean an important mechanism for achieving balance of inflammatory responses is missing (Table I) . Lacking this control, larger than normal amounts of chemotactic factors would be generated by complementdependent mechanisms (Table II) . With more chemotactic factors being generated and with no natural mechanism to inactive these inflammatory mediators, the stage would be set for inordinate delivery of neutrophils (and their enzymes) to inflammatory exudates. The excessive delivery of cells along with the lack of a natural inhibitor to block the action of trypsin-like enzymes from the leukocytes would make for a highly disadvantageous situation. In view of the data presented here, it would seem appropriate to consider modifying the theories of the pathogenesis of pulmonary emphysema in patients who lack ai-AT. ACKNOWLEDGMENTS These studies were supported in part by National Institutes of Health Grant AI-09651-02.
